Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/01/23
Why Earnings Season Could Be Great for Corcept Therapeutics (CORT)Zacks Investment Research • 10/31/23
Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)GlobeNewsWire • 10/26/23
Corcept Therapeutics (CORT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 10/26/23
Corcept Therapeutics: Far More Constructive With Korlym Resolve (Rating Upgrade)Seeking Alpha • 08/26/23
Corcept's Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)GlobeNewsWire • 07/17/23
Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales GuidanceZacks Investment Research • 05/04/23
Corcept Therapeutics (CORT) Lags Q4 Earnings and Revenue EstimatesZacks Investment Research • 03/01/23